An integrated pharmacy-based program improved medication prescription and adherence rates in diabetes patients

Health Affairs

Volumn 31, Issue 1, 2012, Pages 120-129

  Brennan, A Troyen ^a   Dollear, J Timothy ^a   Hu, Min ^a   Matlin, S Olga ^a   Shrank, H William ^b   Choudhry, K Niteesh ^a,b   Grambley, William ^a  

^a CVS Caremark   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALLOXAN DIABETES MELLITUS; ARTICLE; CHRONIC DISEASE; CLINICAL EVALUATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; FEMALE; HUMAN; INVESTMENT; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT COUNSELING; PHARMACIST; PHARMACY; PHYSICIAN; PRESCRIPTION; TELEPHONE;

DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH PROMOTION; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PHARMACEUTICAL SERVICES;

EID: 84855670216     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2011.0931     Document Type: Article

References (34)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information for diabetes and prediabetes in the United States, 2011 [Internet]. Atlanta (GA): CDC; 2011 [cited 2011 Dec 7]. Available from: http://www.cdc.gov/diabetes/ pubs/pdf/ndfs_2011.pdf
2. American Diabetes Association. Diabetes statistics [Internet]. Alexandria (VA): ADA; 2011 [cited 2011 Dec 2]. Available from: http:// www.diabetes.org/diabetes-basics/ diabetes-statistics/
3. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001; 26(5):331-42.
4. Hertz RP, Unger AN, Lustik MB. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. Clin Ther. 2005;27(7):1064-73.
5. American Diabetes Association. Standards of medical care in diabetes- 2011. Diabetes Care. 2011; 34(Suppl 1):S11-61.
6. Cutrona SL, Choudhry NK, Fischer MA, Servi A, Liberman JN, Brennan TA, et al. Modes of delivery for interventions to improve cardiovascular medication adherence. Am J Manag Care. 2010;16(12):929-42.
7. Symmetry. An overview of Symmetry pharmacy risk groups [Internet]. Eden Prairie (MN): Ingenix (now Optum Insight); 2010 [cited 2011 Dec 8]. Available from: http://www .symmetry-health.com/ products/product_SPRG.php
8. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986; 73(1):13-22.
9. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002; 27(4):299-309.
10. Kruskal WH, Wallis WW. Use of ranks in one-criterion variance analysis. J Am Stat Assoc. 1952; 47(260):583-621.
11. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care. 2008; 46(11):1125-33.
12. Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff (Millwood). 2011;30(1):91-9.
13. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-30.
14. DiMatteo RM, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40(9):794-811.
15. Shrank WH, Asch SM, Adams J, Setodji C, Kerr EA, Keesey J, et al. The quality of pharmacologic care for adults in the United States. Med Care. 2006;44(10):936-45.
16. Boccuzzi SJ, Wogen J, Fox J, Sung JC, Shah AB, Kim J. Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes Care. 2001;24(8):1411-5.
17. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic patients. J Int Med Res. 2002;30(1):71-9.
18. Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care. 2004;27(9): 2149-53.
19. McCall N, Cromwell J. Results of the Medicare Health Support diseasemanagement pilot program. N Engl J Med. 2011;365(18):1704-12.
20. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355(9200): 253-9.
21. Kshirsagar AV, Joy MS, Hogan SL, Falk RJ, Colindres RE. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. Am J Kidney Dis. 2000;35(4):695-707.
22. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-9.
23. Pyǒräla K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20(4):614-20.
24. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;287(24):3215-22.
25. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001-9.
26. Godley PJ, Maue SK, Farrelly EW, Frech F. The need for improved medical management of patientswith concomitant hypertension and type 2 diabetes mellitus. Am J Manag Care. 2005;11(4):206-10.
27. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Effectiveness of interventions by community pharmacists to improve patient adherence to chronic medication: a systematic review. Ann Pharmacother. 2005;39(2):319-28.
28. Cranor CW, Christensen DB. The Asheville Project: short-term outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash). 2003;43(2):149-59.
29. Cranor CW, Bunting BA, Christensen DB. The Asheville Project: long-term clinical and economic outcomes of a community pharmacy care program. J Am Pharm Assoc (Wash). 2003;43(2):173-84.
30. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review. Manag Care Interface. 2006;19(7):31-41.
31. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA. 2002;288(22):2868-79.
32. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effects of the angiotensin-receptor agonist irbesartan in patients with nepropathy due to type 2 diabetes. N Engl J Med. 2001; 345(12):851-60.
33. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care. 2000;23(7):888-92.
34. Shrank WH, Choudhry NK, Liberman JN, Brennan TA. The use of generic drugs in prevention of chronic disease is far more costeffective than thought, and may save money. Health Aff (Millwood). 2011;30(7):1351-7.